Market Research Logo

Global Paediatric Vaccine Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

Global Paediatric Vaccine Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

Pediatric vaccines are given to a children in its age from 0 – 18 years of age. Congenital Zika is one of the latest pediatric vaccine which found relation in davsstating defects in infants and Zika virus. This leads to contribute in the growth of the pediatric vaccine market with a CAGR of approx 15.65% during forecast period 2016-2023.The global pediatric vaccine market is driven by increasing government focus on immunization programs , Increase in the number of disease among children such as TB, Hepatitis etc. and government funding for the vaccine development. High growth of healthcare sector globally and increase in the expenditure in health industry are the opportunity for the players involved in the pediatricpaedaitic vaccine market to grow. However, huge capital investment and stringent government regulation for the development of new vaccines and standrads to be followed by governmnrt regarding pediatric vaccine is hampering the demand of the pediatric vaccine market. The major challenge faced by pediatric vaccine market are vaccine cost and inadequate access to vaccine.

Geographically the pediatric vaccine market is bifurcated into North America, Europe, Asia Pacific and RoW. North America gained highest revenue share and is dominating region in pediatric vaccine market. Introduction of new vaccines for all type of diseases and rise in the frequency of occurrence of infectious diseases such as diphtheria, tuberculosis, hepatitis, and pneumococcal disease is aiding the growth of pediatric vaccine market in North America. Moreover, Asia Pacific is the fastest growing region in global pediatric vaccine market due to high annual birth rate which increase the pediatric population in Asian countries such as India, China etc.

Global pediatric vaccine market is segmented on the basis of technology, type, disease indication and end-user. On the basis of disease indication, the pediatric vaccine market is classified as MMR, DTP, influenza, hepatitis, meningococcal disease, pneumococcal disease, human papilloma virus, polio, rotavirus, varicella and others. The technology used in the pediatric market includes conjugate vaccines, inactivate & subunit vaccines live attenuated vaccines, toxoid vaccines and recombinant vaccines. Type is segmented into monovalent vaccines and multivalent vaccines. Monovalent vaccine segment held maximum market share in term of revenue and expected to continue to grow throughout the forecast period 2016-2023. Pneumococcal disease is the growing segment due to increase in the number of patients of pneumococcal infection. The end-user of pediatric vaccine market includes pediatric and adults.

Some of the major players in the pediatric vaccine market are Pfizer, Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), Merck & Co., Inc. (U.S.), Medimmune, LLC (U.S.), Astellas Pharma Inc. (JAPAN) and Others. These companies using various strategies such as merger & acquisition, collaboration, partnership and product launch.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2.MARKET OVERVIEW
2.1. GLOBAL PEDIATRIC VACCINE MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360 DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS&TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3.MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. HIGH PREVALENCE OF DISEASES
3.1.2. RISING GOVERNMENT AND NON-GOVERNMENT FUNDING FOR VACCINE DEVELOPMENT
3.1.3. INCREASING INVESTMENTS BY COMPANIES
3.1.4. INCREASING GOVERNMENT FOCUS ON IMMUNIZATION PROGRAMS
3.1.5. TECHNOLOGICAL ADVANCEMENT IN VACCINE
3.2. MARKET RESTRAINTS
3.2.1. HUGE CAPITAL INVESTMENTS
3.2.2. STRINGENT REGULATIONS
3.3. MARKET OPPORTUNITIES
3.3.1. HIGH GROWTH OF HEALTHCARE SECTOR IN EMERGING MARKETS
3.3.2. THERAPEUTIC VACCINES
3.3.3. INCREASE IN HEALTH EXPENDITURE
3.4. MARKET CHALLENGES
3.4.1. INADEQUATE ACCESS TO VACCINES
3.4.2. VACCINE PRICING
4.MARKET SEGMENTATION
4.1. GLOBAL PEDIATRIC VACCINE MARKET BY TECHNOLOGY
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. GLOBAL CONJUGATE VACCINES MARKET
4.1.5.1.1. APPLICATION
4.1.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.5. KEY CONCLUSIONS
4.1.5.2. GLOBAL INACTIVATED AND SUBUNIT VACCINES MARKET
4.1.5.2.1. APPLICATION
4.1.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.5. KEY CONCLUSIONS
4.1.5.3. GLOBAL LIVE ATTENUATED VACCINES MARKET
4.1.5.3.1. APPLICATION
4.1.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.3.5. KEY CONCLUSIONS
4.1.5.4. GLOBAL TOXOID VACCINES MARKET
4.1.5.4.1. APPLICATION
4.1.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.4.5. KEY CONCLUSIONS
4.1.5.5. GLOBAL RECOMBINANT VACCINES MARKET
4.1.5.5.1. APPLICATION
4.1.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.5.5. KEY CONCLUSIONS
4.2. GLOBAL PEDIATRIC VACCINE MARKET BY TYPE
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL MONOVALENT VACCINES MARKET
4.2.5.1.1. APPLICATION
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.5. KEY CONCLUSIONS
4.2.5.2. GLOBAL MULTIVALENT VACCINES MARKET
4.2.5.2.1. APPLICATION
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.5. KEY CONCLUSIONS
4.3. GLOBAL PEDIATRIC VACCINE MARKET BY DISEASE INDICATION
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. GLOBAL PNEUMOCOCCAL DISEASE MARKET
4.3.5.1.1. APPLICATION
4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.5. KEY CONCLUSIONS
4.3.5.2. GLOBAL DTP MARKET
4.3.5.2.1. APPLICATION
4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.5. KEY CONCLUSIONS
4.3.5.3. GLOBAL INFLUENZA MARKET
4.3.5.3.1. APPLICATION
4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.3.5. KEY CONCLUSIONS
4.3.5.4. GLOBAL HUMAN PAPILLOMA VIRUS MARKET
4.3.5.4.1. APPLICATION
4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.4.5. KEY CONCLUSIONS
4.3.5.5. GLOBAL MENINGOCOCCAL DISEASE MARKET
4.3.5.5.1. APPLICATION
4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.5.5. KEY CONCLUSIONS
4.3.5.6. GLOBAL POLIO MARKET
4.3.5.6.1. APPLICATION
4.3.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.6.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.6.5. KEY CONCLUSIONS
4.3.5.7. GLOBAL ROTAVIRUS MARKET
4.3.5.7.1. APPLICATION
4.3.5.7.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.7.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.7.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.7.5. KEY CONCLUSIONS
4.3.5.8. GLOBAL HEPATITIS MARKET
4.3.5.8.1. APPLICATION
4.3.5.8.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.8.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.8.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.8.5. KEY CONCLUSIONS
4.3.5.9. GLOBAL MMR MARKET
4.3.5.9.1. APPLICATION
4.3.5.9.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.9.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.9.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.9.5. KEY CONCLUSIONS
4.3.5.10. GLOBAL VARICELLA MARKET
4.3.5.10.1. APPLICATION
4.3.5.10.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.10.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.10.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.10.5. KEY CONCLUSIONS
4.3.5.11. GLOBAL OTHERS MARKET
4.3.5.11.1. APPLICATION
4.3.5.11.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.11.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.11.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.11.5. KEY CONCLUSIONS
4.4. GLOBAL PEDIATRIC PAEDIATRIC VACCINE MARKET BY END-USER
4.4.1. MARKET DEFINITION AND SCOPE
4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.4.4. OPPORTUNITY MATRIX
4.4.5. MARKET SEGMENTATION
4.4.5.1. GLOBAL PEDIATRIC VACCINE MARKET
4.4.5.1.1. APPLICATION
4.4.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.1.5. KEY CONCLUSIONS
4.4.5.2. GLOBAL ADULTS VACCINE MARKET
4.4.5.2.1. APPLICATION
4.4.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.2.5. KEY CONCLUSIONS
5.COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS &ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
6.GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL PEDIATRIC VACCINE MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRIAL END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7.COMPANY PROFILES
7.1. PFIZER, INC. (U.S.)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. GLAXOSMITHKLINE, PLC. (U.K.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.2.6. STRATEGIC ANALYSIS
7.3. MERCK & CO., INC. (U.S.)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.3.6. STRATEGIC ANALYSIS
7.4. SANOFI PASTEUR (FRANCE)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. EMERGENT BIOSOLUTIONS, INC. (U.S.)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. JOHNSON & JOHNSON (INDIA)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.6.6. STRATEGIC ANALYSIS
7.7. MEDIMMUNE, LLC (U.S.)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.7.6. STRATEGIC ANALYSIS
7.8. ASTELLAS PHARMA INC. (JAPAN)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.8.6. STRATEGIC ANALYSIS
7.9. SERUM INSTITUTE OF INDIA (INDIA)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.9.6. STRATEGIC ANALYSIS
7.10. ZYDUA CADILA (INDIA)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11. EMERGENT BIOSOLUTIONS INC. (U.S.)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. MITSUBISHI TANABE PHARMA. (JAPAN)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. TAKEDA PHARMACEUTICAL (JAPAN)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. SINOVAC BIOTECH (CHINA)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. PANACEA BIOTEC(INDIA)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
7.16. OTHERS
7.16.1. OVERVIEW
7.16.2. PRODUCT PORTFOLIO
7.16.3. KEY INNOVATION SECTOR
7.16.4. STRATEGIC INITIATIVES
7.16.5. SCOT ANALYSIS
7.16.6. STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL PEDIATRIC VACCINE MARKET BY TECHNOLOGY 2014-2023 ($ MILLION)
GLOBAL CONJUGATE VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL INACTIVATED AND SUBUNIT VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL LIVE ATTENUATED VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL TOXOID VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL RECOMBINANT VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL PEDIATRIC VACCINE MARKET BY TYPE 2014-2023 ($ MILLION)
GLOBAL MONOVALENT VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL MULTIVALENT VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL PEDIATRIC VACCINE MARKET BY DISEASE INDICATION 2014-2023 ($ MILLION)
GLOBAL PNEUMOCOCCAL DISEASE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL DTP MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL INFLUENZA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL HUMAN PAPILLOMA VIRUS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL MENINGOCOCCAL DISEASE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL POLIO MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL ROTAVIRUS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL HEPATITIS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL MMR MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL VARICELLA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL PEDIATRIC VACCINE MARKET BY END USER 2014-2023 ($ MILLION)
GLOBAL PEDIATRIC VACCINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL ADULTS VACCINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
NORTH AMERICA PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
EUROPE PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
ASIA PACIFIC PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
REST OF THE WORLD PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
LIST OF FIGURES
GLOBAL CONJUGATE VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL INACTIVATED AND SUBUNIT VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL LIVE ATTENUATED VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL TOXOID VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL RECOMBINANT VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL MONOVALENT VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL MULTIVALENT VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL PNEUMOCOCCAL DISEASE MARKET 2014-2023 ($ MILLION)
GLOBAL DTP MARKET 2014-2023 ($ MILLION)
GLOBAL INFLUENZA MARKET 2014-2023 ($ MILLION)
GLOBAL HUMAN PAPILLOMA VIRUS MARKET 2014-2023 ($ MILLION)
GLOBAL MENINGOCOCCAL DISEASE MARKET 2014-2023 ($ MILLION)
GLOBAL POLIO MARKET 2014-2023 ($ MILLION)
GLOBAL ROTAVIRUS MARKET 2014-2023 ($ MILLION)
GLOBAL HEPATITIS MARKET 2014-2023 ($ MILLION)
GLOBAL MMR MARKET 2014-2023 ($ MILLION)
GLOBAL VARICELLA MARKET 2014-2023 ($ MILLION)
GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
GLOBAL PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
GLOBAL ADULTS VACCINE MARKET 2014-2023 ($ MILLION)
UNITED STATES (U.S.) PAEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
CANADA PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
UNITED KINGDOM (UK) PAEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
FRANCE PEDIATRIC VACCINE MARKETMARKE 2014-2023 ($ MILLION)
GERMANY PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
SPAIN PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
ROE PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
INDIA PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
CHINA PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
JAPAN PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
AUSTRALIA PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
ROAPAC PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
LATIN AMERICA PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)
MENA PEDIATRIC VACCINE MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report